Rhino-orbito-cerebral mucormycosis : report of 9 cases
10.3760/cma.j.issn.1673-0860.2014.06.002
- VernacularTitle:鼻眶脑型毛霉菌病九例
- Author:
Hai ZHANG
1
;
Gang LIU
;
Wei HANG
;
Jinling ZHANG
Author Information
1. 300060,天津市环湖医院耳鼻咽喉头颈外科
- Keywords:
Mucormycosis;
Paranasal sinus diseases;
Orbital diseases;
Brain diseases;
Endoscopy;
Otorhinolaryngologic surgical procedures
- From:
Chinese Journal of Otorhinolaryngology Head and Neck Surgery
2014;49(6):446-451
- CountryChina
- Language:Chinese
-
Abstract:
Objective To present the clinical characteristics and combination therapy of rhinoorbito-cerebral mucormycosis.Methods The clinical data of 9 patients with rhino-orbito-cerebral mucormycosis treated between January 2008 and January 2013 were analyzed retrospectively.The clinical features,diagnosis,pathological characteristics,surgical technique and combination therapy were summarized.All the patients were treated with nasal endoscopic surgery and combined drug therapy.Results Nine patients were under the state of systemic immunosuppression.Two patients died of intracranial infection.One patient with the symptom of headache was first alleviated after treatment,with visual acuity recovered partially,but this patient died 4 months later due to recurrence of mucormycosis and intracranial infection.Two patients with headache recovered after treatment,the visual acuity recovered to the hand movement,endoscopic examination of surgical cavity was clean and epithelialized,with no recurrence,still alive 5 years up to now.The symptom of headache in another 4 patients disappeared after treatment,visual acuity improved significantly,endoscopic surgical cavity was clean,follow-up with no recurrence,survived more than 2 years,and were still in the treatment of primary disease.Conclusion Rhino-orbito-cerebral mucormycosis is a serious chance infectious disease under the state of systemic immunosuppression,the development is rapid and the mortality rate is high,early diagnosis and combined treatment with nasal endoscopic surgery is necessary.